The World Health Organization (WHO) granted emergency permission to a second Covid-19 vaccine made in China on Tuesday.
WHO officially recognized the Sinovac-CoronaVac COVID-19 vaccine for emergency use, providing assurance to nations, funders, procuring agencies, and communities that it satisfies international safety, efficacy, and production criteria.
Sinovac, a Beijing-based pharmaceutical business, manufactures the vaccine.
The WHO assessment of the Sinovac-CoronaVac vaccine included on-site inspections of the manufacturing facility.
The Sinovac-CoronaVac vaccination is inactivated. Its low storage requirements make it relatively manageable and ideal for low-resource environments.
According to the WHO’s Strategic Advisory Group of Experts (SAGE), the vaccine prevents Covid-19 symptoms in 51% of those who receive it.
On May 7, WHO approved another vaccine manufactured by the Chinese company Sinopharm.
The Covid-19 vaccines developed by BioNTech/Pfizer, AstraZeneca, Johnson & Johnson, and Moderna have also been approved for emergency use by the WHO.
Countries that do not have their own medical regulating authority frequently utilize the WHO decision as a guideline for introducing a vaccine, although the United States and the European Union, for example, have their own regulatory authorities.